Aradigm to raise additional $400,000 in registered direct offering
This offering is in addition to the offering Aradigm announced on February 23, 2009, relating to the sale of approximately 41 million shares of common stock for gross
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.